We continue to see worrisome commentary about market valuations, with hand-wringing about whether the stock market is overvalued or might be in a bubble… and it can get a bit draining, frankly. Caution is important, diversification is important, but worrying does us little good. Yes, investors are paying a steep price for anticipated growth in […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
Saving Jack Kerouac
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Leon Cooperman is probably known to most of you, he may well be the biggest “CNBC name” at today’s session — he runs Omega Advisors, a $10 billion partnership/hedge […]
The Gain from Pain Mainly Explained
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He choses his own topics, and his words and opinions are his own. Part one of this series is here if you missed it. Enjoy!] “The heat was hot and the ground was dry but the air was full of sound. I’ve […]
NASH: An All-Too-Common Liver Disease and a Company Aiming to Treat It
[ed. note: Gumshoe readers have been delighted with the biotech stock discussion led by one of our readers, who has gone by the name karmaswimswami as he has shared hundreds of useful comments — so we’ve asked him to come on as a formal contributor, he’ll be sharing a column with the Irregulars and talking […]
Comments
Steve take a look at Travis Real Money Portfolio. The spreadsheet has 3 of those stocks with stop loss triggers from Tra...
$FYI - PV-Tech Newsletter: US Edition - 4/11/2019 Some of todays articles; China to back-up Jinko and LONGi in...
Here's what I wrote in the ...
It is not necessarily profitable to predict recessions, and it is also almost impossible to do so with any degree of acc...
What I am not sure on is do they pay 11% per month on Rent Checks From the Government REIT's or is it accrued for the ye...
Any "cure" for any potentially fatal disease would be a tremendous blockbuster for the company that develops it. It is t...
I laughed out loud too. I love how Travis’s tears these newsletters apart. But I’m not sure which is worse - inve...
Fire Arm Daily Please find below a message from our advertising sponsor. Our email newsletter is a free service to you ...
Weather forecasters have made amazing progress using "big data," probably much more than most investment forecasters -- ...
Speaking of "security", how secure are our finances in light of: "New Law Gives Banks Ability to Seize Your Accounts"...
I've gotten the new pitch for the same thing with a "Act before Feb. 19th" pitch. Thanks for the info....
The situation has been created by 50 years of unlimited debt spending with the Congress being bought off and derelict in...
Gumshoe, you are AWESOME!!! I think people like Zachary Scheidt should be thrown in Jail for scamming innocent people. T...
William, I thank you kindly for your advice and hope to act early in Feb. Sonny...
James Altucher is not eccentric, unconventional or a kook. In my opinion, this is all an act. He thinks his acting will...
Many years ago,I subscribed to the Weiss Ultimate Portfolio. Their strategy of only buying stocks with the highest WEI...
Left identified INGN as his next short target, May 24 when it was at 170. It momentarily dropped to 157 but then went o...
Travis, Thanks for great honest writings and insights. Just a question: Instead of wait for your weekly update. Is it po...
Interesting, since I do like everything not of this planet. It will be interesting to see which occurs first...a drug c...
where my rent check...
I did!...
Yes where is my late checks of $2748.00?...
Writing is very good. Both Rickards and King graduated from big time law schools, they have been trained to write convi...
Just got a chance to listen to Trevena(TRVN)Jefferies presentation by Max Gowen(who is a great speaker and leading this ...
Nice article on Actavis (ACT). http://www.ft.com/intl/cms/s/0/472bfe98-d279-11e4-ae91-00144feab7de.html?ftcamp=crm/emai...
Actavis (ACT) price target raised to 373.00 by BMO Capital. http://www.americanbankingnews.com/2015/03/18/actavis-plc-p...
Actavis $ACT to issue $20B in corporate bonds. Not sure what big deal Brent Saunders is mulling next, but it is likely t...
I went long on Irish roll-up Actavis $ACT last year as a speculation on it being a lovely tax inversion play for a US ma...
Actavis (ACT) swallowing companies left and right. http://www.ddn-news.com/index.php?newsarticle=9210 Cheers,Glenn...
Hi all: My respect goes out to the retired and active service military members here, for doing something I would not ...
A couple of updates: GILD shares are sagging in part on concern that ABBV, whose HCV regimen is up for FDA approval ...
YES!!!! Durata Therapeutics to be acquired by Actavis (ACT) for $23.00/share in cash, or ~$675 million in the aggregate...
$PFE to do tax inversion takeover of Actavis $ACT? Would be quite good fit, I feel....